98%Confidence
0Views
FDASource
2026-04-18Date
Summary
Amneal Pharmaceuticals' product mix-up between magnesium sulfate and tranexamic acid represents a critical medication error risk with potentially fatal consequences. This unclassified but serious deviation suggests fundamental packaging and quality control failures.
Actionable: Immediately quarantine all affected Amneal IV products and report any suspected mix-ups to regulatory authorities.
AI Confidence: 98%
Data Points
firmAmneal Pharmaceuticals, LLC
classificationNot Yet Classified
statusOngoing
distributionU.S.A. Nationwide
productMagnesium Sulfate in Water for Injection, 4g/100 mL (40mg/mL) IV bag, further packaged in cartons of 12 x 100 mL IV bags, Rx only, Manufactured by: Am
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now